BIOMARCADORES PARA DIAGNÓSTICO DE ENFERMEDAD INFLAMATORIA INTESTINAL

VolverVolver

Resultados 41 resultados LastUpdate Última actualización 15/10/2019 [18:14:00] pdf PDF

Solicitudes publicadas en los últimos 150 días / Applications published in the last 150 days

Página1 de 2 nextPage   por página


METHODS OF DIAGNOSING INFLAMMATORY BOWEL DISEASE THROUGH RNASET2

NºPublicación: US2019300957A1 03/10/2019

Solicitante:

CEDARS SINAI MEDICAL CENTER [US]

JP_2019509739_A

Resumen de: US2019300957A1

The present invention describes methods of diagnosing inflammatory bowel disease, including but not limited to Crohn's Disease (CD), Ulcerative Colitis (UC), and/or Medically Refractive Ulcerative Colitis (MR-UC), using RNA-SET2, TL1A and/or IFN-Υ. The invention further provides a process for patient identification and/or stratification.

traducir

PATIENT-SPECIFIC BIOMARKERS OF ESCHERICHIA COLI INVASION IN INFLAMMATORY BOWEL DISEASE

NºPublicación: US2019302103A1 03/10/2019

Solicitante:

UNIV CALIFORNIA [US]

Resumen de: US2019302103A1

The present invention provides methods of detecting increased carcinoembryonic antigen-related cell adhesion molecule (CEACAM) protein expression in a biological sample from a patient with a loss of function mutation in a protein tyrosine phosphatase non-receptor type 2 (PTPN2) gene. The invention also provides methods of treating or preventing inflammatory bowel disease (IBD) in a patient with a loss of function mutation in a protein tyrosine phosphatase non-receptor type 2 (PTPN2) gene.

traducir

BACTERIA INDUCING TH1 CELLS

NºPublicación: EP3546566A1 02/10/2019

Solicitante:

UNIV KEIO [JP]

JP_WO2018084172_A1

Resumen de: EP3546566A1

The result of orally administering saliva derived from a Crohn's disease patient or an ulcerative colitis patient to germ-free mice has revealed that Th1 cells markedly increased in the colons. Further, from the bacterial microbiota in the intestines of the mice in which such an increase in Th1 cells were observed, bacteria have been successfully isolated which caused strong Th1 cell induction in the colon upon intestinal colonization.

traducir

Methods of Treating Crohn's Disease with an Anti-NKG2D Antibody

NºPublicación: US2019292265A1 26/09/2019

Solicitante:

JANSSEN BIOTECH INC [US]

MX_2019001958_A

Resumen de: US2019292265A1

The present invention is directed to methods for treating Crohn's Disease with an antibody that binds NKG2D. In particular, it relates to dosing regimens for administration of an anti-NGK2D antibody. It also relates to methods of selecting patients for treatment with an anti-NKG2D antibody.

traducir

Polycyclic amines as opioid receptor modulators

NºPublicación: AU2018236130A1 19/09/2019

Solicitante:

WANG XIAODONG

Resumen de: AU2018236130A1

The present invention provides a genus of polycyclic amines that are useful as opioid receptor modulators. The compounds of the invention are useful in both therapeutic and diagnostic methods, including for treating pain, neurological disorders, cardiac disorders, bowel disorders, drug and alcohol addiction, drug overdose, urinary disorders, respiratory disorders, sexual dysfunction, psoriasis, graft rejection or cancer.

traducir

SYSTEM FOR DIAGNOSING AND TREATING MICROVASCULAR OBSTRUCTIONS

NºPublicación: US2019275248A1 12/09/2019

Solicitante:

CORFLOW THERAPEUTICS AG [CH]

WO_2019173758_A1

Resumen de: US2019275248A1

Devices for the diagnosis and treatment of microvascular obstruction (MVO) and other dysfunctional diseases of the microvasculature of many organs, including the heart. The present subject matter provides novel devices and methods to detect and measure or treat MVO in real time during scenarios such as invasive angiographic/therapeutic procedures. Such procedures include therapy for organ systems including the heart (acute myocardial infarction-primary percutaneous coronary intervention (PPCI)), brain stroke (CVA), bowel ischemia/infarction, pulmonary emboli/infarction, critical limb ischemia/infarction, renal ischemia/infarction, and others. Using methods of the invention, a system comprising specialized infusion and sensing catheter, diagnostic agents, therapeutic agents, and control console with specialized algorithms can both diagnose and treat MVO by eliminating the microvascular clot and debris causing the obstruction. The techniques involve a combination of novel devices, methods, and software to simultaneously diagnose and treat MVO.

traducir

SYSTEM FOR DIAGNOSING AND TREATING MICROVASCULAR OBSTRUCTIONS

NºPublicación: WO2019173758A1 12/09/2019

Solicitante:

CORFLOW THERAPEUTICS AG [CH]
SCHWARTZ ROBERT S [US]
HOEM JON HELGE [CH]
ROTHMAN MARTIN T [US]

US_2019275248_A1

Resumen de: WO2019173758A1

Devices for the diagnosis and treatment of microvascular obstruction (MVO) and other dysfunctional diseases of the microvasculature of many organs, including the heart. The present subject matter provides novel devices and methods to detect and measure or treat MVO in real time during scenarios such as invasive angiographic/therapeutic procedures. Such procedures include therapy for organ systems including the heart (acute myocardial infarction - primary percutaneous coronary intervention (PPCI)), brain stroke (CVA), bowel ischemia/infarction, pulmonary emboli/infarction, critical limb ischemia/infarction, renal ischemia/infarction, and others. Using methods of the invention, a system comprising specialized infusion and sensing catheter, diagnostic agents, therapeutic agents, and control console with specialized algorithms can both diagnose and treat MVO by eliminating the microvascular clot and debris causing the obstruction. The techniques involve a combination of novel devices, methods, and software to simultaneously diagnose and treat MVO.

traducir

NANOVESICLES DERIVED FROM COPROCOCCUS SP. BACTERIA, AND USE THEREOF

NºPublicación: WO2019172607A1 12/09/2019

Solicitante:

MD HEALTHCARE INC [KR]

Resumen de: WO2019172607A1

The present invention relates to vesicles derived from Coprococcus sp. bacteria, and a use thereof. The present inventors experimentally confirmed that: compared to those of a normal person, the vesicles are significantly reduced in clinical samples from patients with breast cancer, ovarian cancer, bladder cancer, myocardial infarction, cardiomyopathy and atrial fibrillation; and when the vesicles isolated from a strain are administered, the secretion of inflammatory mediators by pathogenic vesicles, such as vesicles derived from Escherichia coli, is notably inhibited. Thus, the vesicles derived from Coprococcus sp. bacteria, according to the present invention, may be usefully employed for the purpose of developing: a method for diagnosing breast cancer, ovarian cancer, bladder cancer, myocardial infarction, cardiomyopathy or atrial fibrillation; and a composition for preventing, treating or improving gastritis, stomach cancer, colitis, colorectal cancer, breast cancer, ovarian cancer, bladder cancer, myocardial infarction, cardiomyopathy, atrial fibrillation or inflammatory diseases.

traducir

MODULATION OF INTESTINAL EPITHELIAL CELL DIFFERENTIATION, MAINTENANCE AND/OR FUNCTION THROUGH T CELL ACTION

NºPublicación: US2019263912A1 29/08/2019

Solicitante:

BROAD INST INC [US]
MASSACHUSETTS INST TECHNOLOGY [US]
MASSACHUSETTS GEN HOSPITAL [US]

WO_2018089386_PA

Resumen de: US2019263912A1

An atlas of intestinal epithelial cells, intestinal epithelial stem cells and intestinal immune cells identifies new cell populations, markers, networks, and responses to stimuli. Intestinal T cells drive intestinal epithelial cell differentiation and activity. Accordingly, disclosed are methods of modulating intestinal epithelial cell differentiation, maintenance and/or function, related methods for the treatment of disease, including IBD. Also disclosed are methods and kits for identifying cell types, their differentiation, homeostasis and activation.

traducir

COMPOSITIONS AND METHODS FOR PROMOTING GUT HEALTH

NºPublicación: WO2019157566A1 22/08/2019

Solicitante:

ST VINCENTS HOSPITAL MELBOURNE LTD [AU]

Resumen de: WO2019157566A1

The present disclosure relates to compositions and methods for the treatment of gastrointestinal disorders such as ulcerative colitis by suppressing and/or promoting the growth of certain bacteria or the activity of certain metabolic pathways. In some embodiments, the disclosure relates to methods and compositions for use in faecal microbiota transplantation (FMT).

traducir

METHODS FOR DIAGNOSING AND TREATING INFLAMMATORY BOWEL DISEASE

NºPublicación: US2019256913A1 22/08/2019

Solicitante:

GENENTECH INC [US]

US_2017233809_A1

Resumen de: US2019256913A1

Biomarkers predictive of responsiveness to integrin beta7 antagonists, including anti-beta7 integrin subunit antibodies, and methods of using such biomarkers are provided. In addition, methods of treating gastrointestinal inflammatory disorders such as inflammatory bowel diseases including ulcerative colitis and Crohn's disease are provided. Also provided are methods of using such predictive biomarkers for the treatment of inflammatory bowel diseases including ulcerative colitis and Crohn's disease.

traducir

GENE SIGNATURES OF INFLAMMATORY DISORDERS THAT RELATE TO THE LIVER

NºPublicación: AU2019210666A1 22/08/2019

Solicitante:

ENTEROME
INSTITUT NATIONAL DE LA RECH AGRONOMIQUE

JP_2019092522_A

Resumen de: AU2019210666A1

This invention is related to the area of characterization of inflammation in relation with the gut microbiota, in metabolic and autoimmune disorders. In particular, it relates to the identification of gene signatures which can be used as a marker predictive of inflammation associated diseases, such as liver-related metabolic disorders, in particular to the evolution of benign steatosis towards its most severe forms (steatohepatitis and cirrhosis) or autoimmune disorders, in particular inflammatory bowel diseases (Crohn's and Ulcerative Colitis).These gene signatures can therefore be used as a means of diagnosis, prognosis, stratification for drug studies, for monitoring patient and for assigning an appropriate treatment.

traducir

A COMPANION DIAGNOSTIC METHOD FOR USE IN THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIETARY INTERVENTIONS OR FAECAL MICROBIOTA TRANSPLANT

NºPublicación: EP3526340A1 21/08/2019

Solicitante:

GENETIC ANALYSIS AS [NO]

CN_110114471_A

Resumen de: WO2018069538A1

The present invention provides a diagnostic method which may be used to determine the likelihood that a subject with Irritable Bowel Syndrome (IBS) will respond to treatment with an IBS intervention diet or faecal microbiota transplant (FMT). In particular, the method may be used to predict, or determine the likelihood of, a positive response of the subject with IBS to treatment with an IBS intervention diet or FMT, especially to determine the likelihood that the dietary intervention or FMT may have a positive (i.e. beneficial) effect on the subject's Gl tract, specifically the Gl tract microbiota, or other symptoms or complications of IBS (e.g. reducing severity thereof). The method of the present invention is based on analysing the abundance of certain bacteria in Gl tract samples, e.g. by nucleic acid analysis.

traducir

METHOD FOR DIAGNOSING IRRITABLE BOWEL SYNDROME VIA BACTERIAL METAGENOMIC ANALYSIS

NºPublicación: WO2019156325A1 15/08/2019

Solicitante:

MD HEALTHCARE INC [KR]

KR_20190094764_A

Resumen de: WO2019156325A1

The present invention relates to a method for diagnosing irritable bowel syndrome via bacterial metagenomic analysis and, more particularly, to a method for diagnosing irritable bowel syndrome by performing bacterial metagenomic analysis using a subject-derived sample and thereby analyzing an increase or decrease in the amount of extracellular vesicles derived from a particular bacterium. Extracellular vesicles secreted from bacteria present in the bowel are absorbed into the body and may have a direct impact on inflammation production and bowel functions, and irritable bowel syndrome is difficult to diagnose early before any symptoms appear, which makes efficient treatment thereof difficult. Thus, via the metagenomic analysis of bacteria-derived extracellular vesicles using a human body-derived sample according to the present invention, the risk of the onset of irritable bowel syndrome can be predicted in advance, allowing a group at risk of the irritable bowel syndrome to be early diagnosed and predicted and delaying the time of the onset or preventing the onset through appropriate care, and a causative agent can be diagnosed even after the onset, increasing the therapeutic effect of the irritable bowel syndrome with a food or drug for controlling the causative agent.

traducir

METHOD FOR DIAGNOSING IRRITABLE BOWEL SYNDROME VIA BACTERIAL METAGENOMIC ANALYSIS

NºPublicación: KR20190094764A 14/08/2019

Solicitante:

MD HEALTHCARE INC [KR]

WO_2019156325_A1

Resumen de: WO2019156325A1

The present invention relates to a method for diagnosing irritable bowel syndrome via bacterial metagenomic analysis and, more particularly, to a method for diagnosing irritable bowel syndrome by performing bacterial metagenomic analysis using a subject-derived sample and thereby analyzing an increase or decrease in the amount of extracellular vesicles derived from a particular bacterium. Extracellular vesicles secreted from bacteria present in the bowel are absorbed into the body and may have a direct impact on inflammation production and bowel functions, and irritable bowel syndrome is difficult to diagnose early before any symptoms appear, which makes efficient treatment thereof difficult. Thus, via the metagenomic analysis of bacteria-derived extracellular vesicles using a human body-derived sample according to the present invention, the risk of the onset of irritable bowel syndrome can be predicted in advance, allowing a group at risk of the irritable bowel syndrome to be early diagnosed and predicted and delaying the time of the onset or preventing the onset through appropriate care, and a causative agent can be diagnosed even after the onset, increasing the therapeutic effect of the irritable bowel syndrome with a food or drug for controlling the causative agent.

traducir

METHOD FOR DETERMINING LIKELIHOOD OF COLORECTAL CANCER DEVELOPMENT

NºPublicación: US2019241970A1 08/08/2019

Solicitante:

HANUMAT CO LTD [JP]
EA PHARMA CO LTD [JP]

KR_20190045146_A

Resumen de: US2019241970A1

The present invention provides a method for determining the likelihood of colorectal cancer development in a human ulcerative colitis patient, the method including: a measurement step of measuring methylation rates of one or more CpG sites present in specific differentially methylated regions in DNA recovered from a biological sample collected from the human ulcerative colitis patient; and a determination step of determining the likelihood of colorectal cancer development in the human ulcerative colitis patient based on average methylation rates of the differentially methylated regions which are calculated based on the methylation rates measured in the measurement step and a preset reference value or a preset multivariate discrimination expression, in which the reference value is a value for identifying a cancerous ulcerative colitis patient and a non-cancerous ulcerative colitis patient, which is set for the methylation rate of each differentially methylated region, and the multivariate discrimination expression includes, as variables, average methylation rates of one or more differentially methylated regions among the specific differentially methylated regions.

traducir

TREATMENT OF INFLAMMATORY BOWEL DISEASE

NºPublicación: US2019240297A1 08/08/2019

Solicitante:

UNIV LAVAL [CA]

CA_3037779_A1

Resumen de: US2019240297A1

The present invention discloses a novel therapeutic axis NTPDase8 enzyme, P2Y6 and/or P2Y2 receptors, and provides methods, enzymes and/or antagonists for remedying inflammatory bowel diseases.

traducir

PROCESS AND SYSTEM FOR PREDICTING RESPONDERS AND NON-RESPONDERS TO MESALAMINE TREATMENT OF ULCERATIVE COLITIS

NºPublicación: US2019242872A1 08/08/2019

Solicitante:

YACYSHYN BRUCE [US]
YACYSHYN MARY E [US]

AU_2017234659_A1

Resumen de: US2019242872A1

A process and system directed to a more effective, individual based treatment regimen which is built on clinical identified target biomarkers associated with gender differential responses to mesalamine, and includes one or more panels of target biomarkers that distinguishes mesalamine response differences between genders and determines the efficacy of mesalamine for patients being treated for various UC conditions and effectively identifies and validates novel drug targets for new UC therapeutics, new diagnostics and diagnostics standards for UC therapeutic strategies.

traducir

SYSTEMS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE THROUGH PERIPHERAL NERVE STIMULATION

NºPublicación: WO2019143790A1 25/07/2019

Solicitante:

CALA HEALTH INC [US]

Resumen de: WO2019143790A1

Systems and methods for treating symptoms of an inflammatory gastrointestinal disease in a patient with transcutaneous stimulation of a peripheral nerve are disclosed. The method can include any number of positioning a first peripheral nerve effector on the patient's skin to stimulate the peripheral nerve of the patient, delivering a first electrical nerve stimulation signal transcutaneously to the peripheral nerve through the first peripheral nerve effector, and modifying at least one brain or spinal cord autonomic feedback loop relating to release of neurotransmitters from the autonomic nervous system that modulate synthesis of inflammatory biomarkers and reduce inflammation relating to the inflammatory gastrointestinal disease.

traducir

METHODS OF PREDICTING MEDICALLY REFRACTIVE ULCERATIVE COLITIS (mrUC) REQUIRING COLECTOMY

NºPublicación: US2019218616A1 18/07/2019

Solicitante:

CEDARS SINAI MEDICAL CENTER [US]

US_2017044615_A1

Resumen de: US2019218616A1

The present invention relates to methods of predicting the risk for colectomy in a subject with mrUC, by determining the presence or absence of one or more mrUC risk variants. Other embodiment, relate to methods of treating mrUC in a subject and a kit for prognostic use.

traducir

Identification of Pediatric Onset Inflammatory Bowel Disease Loci and Methods for Use Thereof for the Diagnosis and Treatment of the Same

NºPublicación: US2019218612A1 18/07/2019

Solicitante:

CHILDRENS HOSPITAL PHILADELPHIA [US]

US_2011177502_A1

Resumen de: US2019218612A1

Compositions and methods for the detection and treatment of inflammatory bowel disease are provided.

traducir

DIAGNOSTIC AND THERAPEUTIC FOR IBD

NºPublicación: WO2019136529A1 18/07/2019

Solicitante:

NEWSOUTH INNOVATIONS PTY LTD [AU]

Resumen de: WO2019136529A1

The present invention relates to a method of identifying an IBD-associated Campylobacter concisus strain, to a method of detecting the presence of an IBD-associated Campylobacter concisus strain in a subject, and to a method of determining that a subject is at risk of developing active IBD, or is at risk of experiencing an increase in the severity of IBD, or is at risk of activating IBD in remission, comprising detecting in the subject the presence of a an C. concisus strain comprising one or more of the following markers: pICON plasmid; a csep1 gene; and/or a csep1-6bpi gene. The invention also relates to kits and compositions for identifying an IBD-associated Campylobacter concisus strain.

traducir

NANOVESICLE DERIVED FROM PROTEUS GENUS BACTERIA, AND USE THEREOF

NºPublicación: US2019209624A1 11/07/2019

Solicitante:

MD HEALTHCARE INC [KR]

KR_20190003359_A

Resumen de: US2019209624A1

Provided are vesicles derived from bacteria belonging to the genus Proteus and a use thereof. The inventors of the present invention experimentally confirmed that the vesicles was significantly reduced in samples of patients with cancers, allergic-respiratory diseases, cardiovascular diseases, metabolic diseases, or neuropsychiatric diseases, as compared to that of normal people, and the vesicles inhibited the secretion of inflammatory mediators due to pathogenic vesicles and also exhibited anticancer efficacy. Therefore, it is anticipated that the vesicles derived from bacteria belonging to the genus Proteus, according to the present invention, may be usefully used for the development of a method of diagnosing cancer, cardiovascular diseases, metabolic diseases, neuropsychiatric diseases, allergic-respiratory diseases, and inflammatory bowel diseases, and a composition for prevention, treatment, and/or alleviation.

traducir

METHODS OF USING SINGLE NUCLEOTIDE POLYMORPHISMS IN THE TL1A GENE TO PREDICT OR DIAGNOSE INFLAMMATORY BOWEL DISEASE

NºPublicación: US2019211400A1 11/07/2019

Solicitante:

CEDARS SINAI MEDICAL CENTER [US]

US_2017166967_A1

Resumen de: US2019211400A1

This invention provides methods of diagnosing or predicting susceptibility to Inflammatory Bowel Disease by determining the presence or absence of genetic variants in the TL1A gene. In one embodiment, a method of the invention is practiced by determining the presence or absence of TL1A production following Fc-gamma-R activation. In another embodiment, the invention provides methods of treatment of inflammatory bowel disease by inhibition of TL1A.

traducir

METHODS OF PREDICTING COMPLICATION AND SURGERY IN CROHN'S DISEASE

Nº publicación: US2019203295A1 04/07/2019

Solicitante:

CEDARS SINAI MEDICAL CENTER [US]

US_2012073585_A1

Resumen de: US2019203295A1

The present invention relates to prognosing, diagnosing and treating an aggressive form of Crohn's disease characterized by rapid progression to complication and/or surgery from the time of diagnosis. In one embodiment, the prognosis, diagnosis and treatment is based upon the presence of one or more genetic risk factors.

traducir

Página1 de 2 nextPage por página

punteroimgVolver